SBIR/STTR Research Award

Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model

Award identifier 78fb39a2a97f6e5777f44ea939d6f902fb11d82f8cb979a453f1c076050d3070Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$190,720

Program and phase

STTR · Phase I

Award year

2015

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Cytex Therapeutics, Inc.
Proposal award date
2015-09-08
Contract end date
2016-08-31
UEI
G9RMDCWJYGL3
Solicitation number
PA14-072
Topic code
NIAMS

Research abstract

DESCRIPTION provided by applicant The treatment of large cartilage lesions is a difficult clinical problem for which there are few good solutions Left untreated these lesions tend to degenerate to chronic pain and osteoarthritis OA ultimately requiring a total joint replacement For patients suffering from knee OA and in particular unicompartmental OA unicondylar knee arthroplasty UKA is an available first line treatment option that provides many potential advantages over more common total knee replacement procedures However this approach remains controversial due to variable clinical results and high rates of revision associated with current implant designs To overcome the pitfalls associated with current implant designs we have developed a novel tissue engineering therapy for unicondylar resurfacing for knee OA The overall goals of this study are two fold Phase I to repair large osteochondral defects in the knee for which current treatment paradigms are currently contraindicated and Phase II to resurface a diseased femoral condyle in an ovine model of unicompartmental OA Our approach for both phases is based on a high performance three dimensionally D woven scaffold that mimics the biomechanical properties of native articular cartilage at the initial time of cell seeding thus providing a highly functional implant Its unique woven architecture forms to the anatomical curvature of the condyle provides an environment that encourages cell growth and differentiation and is capable of integrating with subchondral bone In Phase I efficacy of the technology will be evaluated in a large full thickness cartilage defect located in the medial condyle of the knee The following groups will be evaluated a defect only control group an acellular scaffold treatment group autologous mesenchyme derived stem cell MSC seeded scaffold group and a tissue engineered treatment group ex vivo cultured scaffold with autologous MSCs At months the regenerative response of all groups will be evaluated histologically and biomechanically The most successful treatment will then be translated to Phase II where an anatomically condyle shaped implant will be used to treat OA All animals in Phase II will be evaluated at and months following repair Functional measurements will be taken pre and postoperatively to evaluate joint function and comfort while sequential radiographs and MRI will be used to assess any morphological changes Histological and biomechanical properties of the joint tissues collected from the treated joint will be compared to those from the contralateral limb negative control to quantify degradative changes Serum synovial fluid and synovium will be analyzed for biomarkers of OA as well as for adverse inflammatory reactions and to test for wear debris in the joint This study will primarily provide valuable data on the ability of out technology to treat a range of cartilage pathology ranging from large cartilaginous defects to unicompartmental OA Secondarily the findings of the study will provide insight into clinical imaging and serum synovial fluid biomarkers that may provide additional information on the predictive validity of such measures in knee OA PUBLIC HEALTH RELEVANCE The aim of this project is to study a biosynthetic implant that can be used for treatment of cartilage pathologies ranging from large defects to unicompartmental knee osteoarthritis while providing significant advantages over typical knee replacement procedures The basis of this work involves the combination of bone marrow derived adult stem cells and a novel high performance three dimensionally woven scaffold that is designed to withstand joint loading and induce differentiation of the stem cells The ultimate goal of this study is to develop tissue engineering technologies that can eventually be used to treat osteoarthritis and other joint diseases

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

22 SBIR/STTR records share this UEI (2007–2023). Reported award amounts total $18,271,228. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.